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ABSTRACT 
There is increasing evidence that agents that target peripheral B cells and in some instances 
plasma cells can exhibit marked effects on relapsing multiple sclerosis. In addition, B cells, 
including plasma cells, within the central nervous system compartment are likely to play an 
important role in disease progression in both relapsing and progressive MS. However, current B 
cell-targeting antibodies may not inhibit these, because of poor penetration into the central 
nervous system and often oligoclonal bands of immunoglobulin persist within the cerebrospinal 
fluid despite immunotherapy. Through targeting B cells and plasma cells in the CNS, it may be 
possible to obtain additional benefit above simple peripheral depletion of B cells. As such there 
are a number of inhibitors of B cell function and B cell depleting agents that have been developed 
for myeloma and B cell leukaemia and lymphoma, which could potentially be used off-label or 
as an experimental treatment for advanced (progressive) MS. 
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HIGHLIGHTS 
● Peripheral B cell responses have been targeted to inhibit active/relapsing multiple sclerosis. 
● Inhibition of advance (progressive) multiple sclerosis may be achieved by targeting B cell 
responses in the CNS. 
● Agents exist that could be used to target such B cell responses and could be used to show 
benefit 
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INTRODUCTION 
Although multiple sclerosis (MS) is historically considered to be a T cell-mediated autoimmune 
disease of the central nervous (CNS), response to therapy has demonstrated that inhibitors of B 
cell activity are potent inhibitors of disease (Stüve et al. 2005; Reviewed in Baker et al. 2017 
and Baker et al. 2018). There is evidence that all current effective disease-modifying therapies 
for relapsing MS interfere with B cell function, either through depletion of B cell numbers or 
inhibition of effector functions, in a manner that reflects their level efficacy in relapsing MS. 
(Gandoglia et al. 2017; Storek et al 2004; Dooley et al. 2015; Reviewed in Baker et al. 2017; 
Ceronie et al. 2018). Strikingly, for any given disease-modifying agent, the degree of memory 
B cell inhibition correlates well with disease-modifying efficacy (Dooley et al. 2015; Reviewed in 
Baker et al. 2017). Indeed, continuous depletion of CD20-expressing B cell subsets has led to 
the licencing of the first agent to treat both relapsing and primary progressive MS (Montalban et 
al. 2017; Hauser et al. 2017; Mulero et al. 2018).   
 
In addition to playing a significant role in driving relapsing biology, B cells are likely to play an 
important role in disease progression, both in the context of relapsing and primary and secondary 
progressive disease, which have active components driven by the adaptive-immune response 
entering the CNS (Lublin 2014) and non-active disease-associated neurodegenerative 
components probably driven by glial-derived immune responses that may be poorly-responsive 
to current disease modifying treatments (Lublin 2014; Montalban et al. 2017; Al Salama 2019; 
Reviewed in Baker et al. 2018). 
 
However, B-cell depleting monoclonal antibodies may not effectively target the B cell 
compartment with the CNS, as antibodies penetrate the CNS poorly (Tran et al. 2014; Reviewed 
in Baker et al. 2018) and oligoclonal bands (OCB) often persist despite therapy (Reviewed in 
Pryce & Baker 2018 and Baker et al. 2018). Therefore, by targeting B cells and plasma cells in 
the CNS (Figure 1), it may be possible to obtain additional benefit above simple peripheral 
depletion of B cells. As such, there are a number of inhibitors of B cell function and B cell 
depleting agents (Figure 1) that have been developed for myeloma and B cell leukaemia and 
lymphoma, which could be used off-label or as an experimental treatment for progressive MS, 
given that lumbar puncture and intraventricular delivery of intrathecal CD20-depleting antibodies 
has so far been disappointing for targeting B cell responses within the CNS (Topping et al. 2016; 
Komori et al. 2016; Bergman et al. 2016). 
  
ANTIBODIES 
Monoclonal antibodies provide the most specific way of targeting particular B cell subsets. 
Indeed, both CD19 and CD20-specific antibodies have been found to inhibit relapsing MS 
(Reviewed in Baker et al. 2017 and Baker et al. 2018). However, as these markers are not 
expressed by plasma cells, it demonstrates that they and immunoglobulin are not essential for 
disease activity (Ireland et al. 2012; Baker et al. 2017a). Whilst these target the mechanisms 
driving relapsing disease (Hauser et al. 2017; Reviewed in Baker et al. 2018), CD20-depleting 
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antibodies also can inhibit, at least active, primary progressive MS (Hawker et al. 2009; 
Montalban et al. 2017). This can be targeted by ocrelizumab and off-label rituximab and other 
antibodies in development), such as ofatumumab ((Du et al. 2017; Bar-Or et al. 2018). However, 
the action against progressive MS may be secondary to inhibition of active disease, rather than 
via a direct neuroprotective effect (Hawker et al. 2009; Castillo-Trivino et al. 2013). Indeed, this 
may not be surprising as monoclonal antibodies fail to significantly enter the CNS (Figure 1), 
CD20-depleting antibodies exhibit limited direct killing of B cells in the CNS (Topping et al. 2016; 
Komori et al. 2016), do not kill plasma cells (Sabatino et al. 2016) and do not initially affect 
immunoglobulin levels and OCB within the cerebrospinal fluid (Castillo-Trivino et al. 2013; 
Sabatino et al. 2016; Studer et al. 2014). Although, there are antibody agents that can target 
plasma cells, as used in myeloma such as: indatuximab (CD138-specific)-ravtansine; 
lorvotuzumab (CD56-specific)-mertansine, CD38 (daratuumumab) and CD27+, memory B cells 
such as varlilumab (Robart & Robart 2016; Schönfeld et al. 2017; Burris et al. 2017), given the 
poor penetration of antibodies (99.9% excluded. Kikuchi et al. 2004; Tran et al. 2014) across 
the blood-brain barrier and the limited killing capacity of intrathecal-administered antibody 
(Topping et al. 2016; Komori et al. 2016), probably due to lack of sufficient effector mechanisms 
for complement fixation and/or antibody dependent cellular cytotoxicity within the CNS (Komori 
et al. 2016), use of antibodies does not appear to be the most optimised method to target B 
cells within the CNS.  However, CD20-depletion could be a base on which to add neuroprotection 
and repair activity as the drug may have immune-reconstitution therapy potential (Baker et al. 
2017). However, B cells form a central part of immunity. As such, continuous B cell depletion is 
associated with reductions in immunoglobulin levels and an increased risk of infection that is 
going to accumulate with time (Hauser et al. 2017; Giovannoni 2018). These risks can be 
significant, and is of interest that the development of ocrelizumab was terminated in other CD20-
responsive autoimmunities because of infection-related fatalities adversely affecting the 
risk:benefit balance (Harigai et al. 2012; Emery et al. 2014). However, it may be possible to 
achieve benefit from pulsed therapies to avoid problems with continuous immunosuppression 
(Baker et al. 2017).  
 
SMALL MOLECULE IMMUNE INHIBITORS 
B cells have a more rapid turnover than T cells and rapidly die in vitro and are susceptible to 
cytostatic agents that kill cells during DNA replication (Baker et al. 2017a). Therefore, B cells 
including both regulatory and effector B cells are particularly sensitive to cytostatic agents 
(Minagawa et al. 1987; O’Neill et al. 1992; Baker et al. 2017a). In animals this can mean that 
B cell therapy can have distinct and opposing activity, dependent on timing of treatments 
(Minagawa et al. 1987; O’Neill et al. 1992; Sefia et al. 2017). Similarly B cell immunotherapy 
can inhibit (Baker et al. 2017; Baker et al. 2018; Sabatino et al. 2018), but in some instances 
augment MS, possibly due to influences on distinct B cell subsets (Kappos et al. 2014; Baker et 
al. 2017). Therefore, actual use will demonstrate where the therapeutic balance resides, but 
targeting memory B cell responses inhibits MS (Baker et al. 2017a). There are a number of 
agents that could be used to target B cells. 
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Cyclophosphamide is prodrug that is metabolised to a cytostatic agent that kills rapidly dividing 
cells and thus can target some B cells by virtue of their activation or by because B cells exhibit 
a higher turnover rate compared to other cells such as T cells (Macallan et al. 2003; Macallan et 
al. 2005). Therefore B cells may be more sensitive to cytostatic agents, although low-dose pulsed 
cyclophosphamide exhibits limited effects on plasma cells and memory B cells (Fassbinder et al. 
2015). However, high-dose (120mg/kg-200mg/kg) cyclophosphamide has been used 
extensively in people with progressive MS, as part of a monotherapy or as part of Haematopoeitic 
Stem Cell Therapy (HSCT) to induce mobilisation of CD34+ stem cells (La Mantia et al. 2007; 
Krishan et al. 2008; Bowen et al 2012; Atkins et al. 2016; Brochet al. 2017). Whilst 
cyclophosphamide and HSCT have exhibited marked impact on relapsing and active MS (Krishan 
et al. 2008; Aktins et al. 2016), people with progression have often continued to progress, 
although some people with advanced (progressive) MS appear to show some benefit (Bowen et 
al. 2012). However, people with MS often poorly tolerate cyclophosphamide, consistent with the 
non-selective activity on dividing cells including hair loss and gastrointestinal problems (La 
mantia et al. 2007; Krishan et al. 2008). Many people continue to show some worsening and 
OCB have persisted (60-160mg/kg) indicating ineffective CNS clearance of B cells within their 
CNS niches (Openshaw et al. 2000; Saiz et al. 2001; Carreras et al. 2003; Nash et al. 2012; 
Bowen et al. 2012). 
  
Mitoxantrone is a type II topoisomerase inhibitor that disrupts DNA synthesis and repair and 
intercalates into DNA bases and kills dividing cells and so may target dividing B cells that are 
turning over (Macallan et al. 2005). Mitoxantrone depletes B cells and notably exhibits a marked 
impact on memory B cell in MS, consistent with its efficacy (Chan et al. 2005; Duddy et al. 2007; 
Baker et al. 2017). Pixantrone, a mitoxantrone analogue, is also a potent depleter of B cells 
(Gonsette et al. 2018). When mitoxantrone was used in combination with CD20-depletion there 
was marked depletion of peripheral blood B cells and also reductions, albeit to a more modest 
and transient level. of B cells with the cerebrospinal fluid that was associated with a positive 
treatment effect (Evdoshenko et al. 2013). Mitoxantrone is used for the treatment of active 
advanced MS (Martinelli Boneschi et al. 2013). It can show a significant but partial efficacy in 
reducing the risk of MS progression and the frequency of relapses in some but not all studies 
(Martinelli Boneschi et al. 2013; Grey Née Cotte et al. 2015). However, mitoxantrone is 
neurotoxic and is actively excluded from the CNS via the action of ABCG2 ATP-binding cassette 
transporter (Dalle et al. 2000; Cotte et al. 2009). The influence on OCB is also limited (Axelsson 
et al. 2013). This coupled with concerns about the risk of cardiotoxicity and therapy-related 
acute leukaemias, limit the value of mitoxantrone (Martinelli Boneschi et al. 2013). 
 
Cladribine produces toxic moieties following phosphorylation of the adeonosine-analogue by 
deoxycytidine kinase and selectively kills, dividing and non-dividing, lymphocytes notably B 
lymphocytes (Giovannoni et al. 2017; Ceronie et al. 2018). Oral cladribine prodrug inhibits 
relapsing MS (Giovannoni et al. 2017). Likewise, parenteral, generic cladribine inhibits disease 
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activity in relapsing and progressive disease (Giovannoni et al. 2017, Rice et al. 2000). Although 
there is a perceived failure in progressive MS (Beutler et al. 1996; Rice et al. 2000), the trials 
were too short to really demonstrate full clinical benefit and there were positive imaging and 
clinical effects (Rice et al. 2000) and unlike any other licenced disease modifying treatment in 
MS, the drug is CNS penetrant (Figure 1) and can be active in the CNS (Kearns et al. 1994; 
Baker et al. 2019). Cladribine probably behaves as chemical anti-CD19 agent, with additional T 
cell inhibitory activity, based on the high expression of deoxcytidine kinase (DCK) in B cells, 
which facilitates cladribine-induced apoptosis of lymphocytes (Cocco et al. 2012; Baker et al. 
2019). It is evident that DCK is expressed on early B cell lineages including immature, mature, 
memory B cells and plasmablasts but is down regulated in plasma cells (Cocco et al. 2012; 
Ceronie et al. 2018; Baker et al. 2019). However, parenteral cladribine has reduced or eliminated 
the occurrence of OCB in some people with MS (Sipe et al. 1994, Rejdak et al. 2018), suggesting 
that it can inhibit the development of plasma cells or that it blocks the factors that promote B 
cell niches within the CNS.  Cladribine like alemtuzumab and ocrelizumab has some immune-
reconstitution therapy potential, with a long-term benefit from a short course of treatment 
(Giovannoni et al. 2018). As such this may also provide an immunomodulatory platform on which 
to layer neuroprotection and repair. 
  
Mycophenolate is a lymphocyte-selective depleting agent that is metabolised in the plasma 
and the liver into mycophenolic acid, which is a reversible inhibitor of inosine monophosphate 
dehydrogenase (IMPDH) involved in de novo purine biosynthesis. This pathway is essential for 
lymphocyte proliferation (Euqui et al. 1991). However, there is limited data concerning benefit 
of use in MS, but it may inhibit active disease (Michel et al. 2014; Xioa et al. 2014; Fakih et al. 
2018). This agent can inhibit B cell activation and differentiation in vitro, although terminally 
differentiated plasma cells appear to less sensitive to the effects of mycophenolate, possibly due 
to down regulation and insensitivity of the IMPDH (Karnell et al. 2011). However there does not 
appear to be gross changes in most B cell subsets following treatment with mycophenolic acid 
in humans, although in some instance plasma cells appeared to be reduced in non-MS conditions 
(Zhao et al. 2012; San Sequndo et al. 2012; Fickenberg et al. 2012). However the influence on 
B cell subsets require study and positive effects on non-active elements of progressive MS have 
yet to be found (Fakih et al. 2018). 
 
B CELL-SELECTIVE INHIBITORS 
Given the success of B cell depletion using CD20 monoclonal antibodies, there is significant 
commercial interest in developing B cell depleting agents or B cell inhibitors. 
  
Brutons tyrosine kinase (BTK) inhibitors reversibly or irreversibly block the BTK enzyme 
that plays a crucial signalling role in B cell development and mutations in BTK are associated 
with X-linked agammaglobulinemia, where B cell fails to mature. BTK inhibitors prevent B cell 
activation and block downstream B cell survival pathways. There are a number of BTK inhibitors 
in clinical development, initially for cancer and the first study in MS has been reported to have 
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a positive impact in active disease using evobrutinib (Montalban et al. 2019). This is a first 
generation BTKi that has been reported to the inhibit lesion formation and the generation of 
relapses in phase II trials (Montalban et al. 2018). This also inhibits macrophage function and 
may thus have additional activities relevant for advanced MS (Alankus et al. 2018). Some first 
generation agents have been approved for treating haematological malignancies and graft versus 
host disease, such as Ibrutinib. This is appears to be a p-glycoprotein substrate, which may limit 
CNS penetration (van Hoppe et al. 2018) and infections following use commonly occur (Tillman 
et al. 2018; Hsiehchen et al. 2018). Second generation inhibitors are been developed that have 
fewer side effects and greater specificity (Wu et al. 2016; Pal Singh et al. 2018). There is 
significant commercial interest in BTKi development and include agents such as PRM226, which 
is a CNS penetrant BTKi, ABBV-105 and HM71224/LY3337641 (Wu et al. 2016; Robak & Robak 
2017; Pal Singh et al. 2018). However, although caution is needed when comparing studies, the 
reduction in the of level formation by evobrutinib does not appear to as marked as found with 
CD20-depletion and this may have implications for staging within the therapeutic ladder of MS 
treatments (Kappos et al. 2011; Montalban et al. 2019). In addition, BTKi have been used to 
augment cancer therapy when used in combination with other agents (Geyer et al. 2019). It 
remains to be seen whether there could be benefit from being used as add-on therapy in MS. 
This will become clearer as more studies are undertaken and published.  
 
Proteosome Inhibitors. The proteasome plays a pivotal role in the control of many cell cycle-
regulatory processes, including regulation of nuclear factor Kappa B activity and control of 
apoptosis (Schenken 2002). Proteasome inhibitors can sensitize cells to induce apoptosis and 
have been used to treated multiple myeloma, using agents such as bortezomib that is partially 
excluded from the CNS by p-glycoprotein (Forn at al. 2016).One could use such an agent to 
make advantage of the finding that p-glycoprotein exclusion pump is down-regulated in MS 
lesions, to selectively target areas of pathology (Al-Izki et al. 2014). However, bortezomib can 
have undesirable side-effects such as the induction of neuropathy (Alé et al. 2014). There are 
second generation inhibitors such as carfilzomib and ixazomib, with more limited neuropathic 
effects (Karademir et al. 2018). These inhibitors target plasma cells, but also have impact on 
activated naïve and memory B cells and may have activity against peripheral autoimmunity 
(Mulder et al. 2013, Alexander et al. 2015). CNS-penetrant proteosome inhibitors such as 
marizomib have been generated (Di et al. 2016). It remains to be seen whether these agents 
will have merit in the treatment of MS and whether they can be used long-term to treat MS, 
especially as proteasome activators may be neuroprotective (Schattling et al. 2019).  
 
B CELL SURVIVAL FACTORS 
There are a number of B cell growth, differentiation and survival factors including interleukin 4, 
Interleukin 6, Interleukin 10 and Interleukin 13, lymphotoxin and tumour necrosis factor, and a 
number of chemokines notably B cell-attracting chemokine 1/CXCL13, which support B cell 
growth and survival (Housley et al. 2016). Many can be inhibited by specific monoclonal 
antibodies such as tocilizumab (IL-6 receptor) and siltuximab (IL-6) and others (Klimatcheva et 
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al. 2015; Beauchemin & Carruthers 2016). However, these will have the same CNS penetration 
issues as agents targeting B cell surface markers and some may have unwanted activities 
(Beauchemin & Carruthers 2016; Kemanetzoglou & Andreadou 2017). Inhibition of B cell 
activating factor (BAFF. TNFLS13B) and a proliferation proliferation-inducing ligand (APRIL) 
serves as a warning that not all B cell inhibitors are beneficial (Reviewed in Baker et al. 2017). 
Atacicept is a fusion protein of the transmembrane activator and calcium modulator and 
cyclophilin-ligand interactor (TACI. TNFRSF13B) receptor that blocks BAFF and APRIL to deplete 
mature B cells and plasma cells, but not memory cells and appears to augment MS relapse 
(Kappos et al. 2014; Sergott et al. 2015; Reviewed in Baker et al. 2017). It is therefore of 
interest that studies with monoclonal inhibition of BAFF using tabalumab did not inhibit lesion 
formation, but importantly it did appear to worsen MS (Silk & Nantz 2018). BAFF stimulates the 
TACI receptor, the BAFF-receptor (TNFRSF13C) expressed by most B lineage cells and the B cell 
maturation antigen receptor (TNFRSF17), which highly expressed by mainly be plasma cells 
(Mackay et al. 2003; Darce et al. 2007). APRIL stimulates TACI, expressed by memory B cells 
and plasma cells (www.biogps,org) and BCMA (Mackay et al. 2003; Darce et al. 2007), but 
interestingly inhibition of BAFF with belimumab does not appear to augment the memory B cell 
response (Ramsköld et al. 2018). Therefore, this not only implicates APRIL as a problematic 
growth factor in MS, importantly if provides yet more evidence to support the hypothesis that 
the memory B cells are central mediators in the pathogenesis of MS (Reviewed in Baker et al. 
2017). 
 
TUMOUR NECROSIS FACTOR INHIBITORS. 
Tumour necrosis factor (TNF) is a plasma cell survival factor and a number of the markers 
involved in B cell development are members of the TNF superfamily such as CD40 and CD27, 
which are MS susceptibility genes (Jourdan et al. 1999, Dendrou et al. 2013; Fliggett et al. 
2014). Inhibitors of TNF are used to treat multiple myeloma indicating the sensitivity of B cells 
to these treatments. Most MS treatments are also active in other autoimmune diseases, but 
inhibition of TNF has been a notable exception and even appears to augment CNS demyelinating 
disease (Kemanetzoglou & Andreadou 2017).  Whilst it has been postulated that TNF inhibition 
can augment memory B cell responses and so drive relapsing MS (Baker et al 2017a), other 
explanations are possible (Kemanetzoglou & Andreadou 2017). As such, because antibodies are 
largely excluded from the CNS, there is a possibly that there is no inhibition of TNF within the 
CNS and therefore no inhibition of local B cell responses occurs in MS, unlike in other TNF 
inhibition-sensitive peripheral autoimmunities.  As such it has been shown that TNF contributes 
to the formation of ectopic B cell follicles and these may contribute to disease progression in MS 
(Paulino et al. 2018, Pryce & Baker 2018; Baker et al. 2018). Peripheral inhibition of TNF has 
been shown to block B cell follicles (Cañete et al. 2009; Pryce & Baker 2018). This would suggest 
benefit may be driven by targeting CNS-derived TNF (Figure 1. Baker et al. 1994). 
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Intrathecal/Ventricular TNF inhibition. There is experimental evidence the local delivery of 
TNF into the CNS offers benefit over systemic delivery (Baker et al. 1994). However, given the 
history of anti-TNF treatment in MS, this approach will be difficult to recruit and undertake. 
  
Phophosphodiesterase 4 (PDE4) Inhibition. There is evidence that PDE4 inhibitors are 
potent TNF inhibitors and consistent with this, rolipram may even augment relapsing MS disease 
(Sommer et al. 1995, Bielekova et al. 2009). However, worsening was not found with Ibudilast 
which also did not inhibit relapsing MS (Barkhof et al. 2010). Ibudilast is a CNS-penetrant 
phosphodiesterase 4 and migration inhibition factor inhibitor that may have some benefit in 
progressive MS, in contrast to pentoxyfylline, and has slowed brain volume loss in MS (Meyers 
et al. 1998; Fox et al. 2018). Whether this targets intrathecal B cell responses is currently 
unknown. 
  
Thalidomide Analogues. Thalidomide is also used to treat myeloma and is a potent inhibitor 
of TNF, however it produces tetragenic effects. There are a number of thalidomide analogues 
that have fewer side effects such as: lenalidomide, pomaldomide and apremilolast. 
Pomalidomide is used to treat multiple myeloma (Gueneau et al. 2018). It remains to be seen 
whether they could target plasma cell responses in the CNS during MS. 
  
VACCINATION THERAPY 
Chimeric Antigen Receptor T cells (CAR-T) Therapy.  A novel immunotherapy has emerged 
for cancer immunotherapy, whereby (CD8) T cells from individuals can be engineered to express 
cell-specific single chain variable antibody fragments that give specificity and signal T cell 
activation following ligation (Ruella & June 2016). Initial targeting constructs have been designed 
to target all CD19 or CD20 B cells (Ruella & June 2016; Zhang et al. 2017; Perales et al. 2018). 
These CART cells would have the capacity to enter the CNS to kill B cells, including the memory 
B cells and plasmablasts, which are the dominant B cell subsets with the CNS (Eggers et al. 
2017). Tisagenlecleucel, which targets CD19 B cells has been licenced after success in cancer 
(Zhang et al. 2016). However, this therapy is not currently reversible and will lead to permanent 
depletion of all CD19 B cells, as they form and they will not directly target long-lived plasma 
cells that do not express CD19. These CAR-T cells will probably lead to the infection problems 
that have been associated with long-term B cell deletion using antibodies. The creation of more 
selective CAR-T and development of the technology for reversible, safer use of CART therapy 
would probably be ideally needed for use in MS (Duong et al. 2017; Perales et al. 2018). 
Recently, B cell maturation antigen (CD269) CAR-T cells have been produced for multiple 
myeloma, which will target  B memory cells and notably plasma cells and may offer real promise 
for targeting pathogenic B cells with the CNS in the future (Cohen et al. 2019). 
 
Epstein Barr Virus vaccination to kill virally-infected B cells. Epstein Barr virus, which may 
be the aetiological trigger of MS, infects B cells and causes expansion of memory B cells (Burns 
et al. 2015, Burns et al. 2016, Reviewed in Baker et al. 2018). These may presentation antigen 
 
10 
 
to T cells to drive MS (Reviewed in Baker et al. 2017). This virus creates survival advantage for 
the B cell and therefore killing of the virus may limit B cell activity. This may be achieved using 
EBV-specific CD8 cytotoxic cells (Pender & Burrows 2014). This approach is being trialled and 
commercially developed for MS and may offer some benefit in progressive MS (Pender MP et al. 
2017). 
  
SUMMARY 
As B cells are increasing been seen as an important pathogenic element of relapsing and 
progressive MS (Baker et al. 2017; Baker et al. 2018) searches for novel agents will increase. 
However, whilst these may offer promise, the failure and potential worsening of some B cell 
inhibitory agents (Sergott et al. 2015), indicates that until appropriate trials are under taken 
their potential efficacy and safety cannot necessarily be predicted (Kappos et al. 2014, Sergott 
et al. 2015). 
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FIGURE 1. Targeting domains for control B cell activity during multiple sclerosis.  
Agents target plasma cells (blue) and/or B cell lineage cells (pink) cells and/or non-B cells 
(transparent), which are either quiescent (Dots) or dividing (Hatch). These can be targeted 
either in the periphery or within the periphery and central nervous system (Grey). 
Immunosuppressive agents that may be of value are shown, although their precise positioning 
is for illustrative purpose and can vary depending on the pharmacokinetic properties of the 
agents. Low activity against plasma cells is based on deoxycytosine levels and may not reflect 
events occurring in MS. BTKi Bruton’s tyrosine kinase. Pi proteasome inhibitor, CY 
cyclophosphamide, CAR Chimeric antigen receptor. 
 
  
